St Jude Medical Inc

Most Recent

  • uploads///eps
    Earnings Report

    What to Expect from St. Jude Medical’s Earnings in 2Q16

    In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.

    By Sarah Collins
  • uploads///Q EPS
    Earnings Report

    Weighing in with Boston Scientific’s 4Q15 Revenues

    Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.

    By Sarah Collins
  • uploads///thv
    Earnings Report

    What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.

    By Sarah Collins
  • Financials

    Overview: Why D.E. Shaw ups position in Liberty Global

    D.E. Shaw upped its position in Liberty Global PLC (LBTYK) that accounted for 0.76% of the company’s U.S. long portfolio in 4Q13.

    By Samantha Nielson
  • uploads///revenue estimates
    Earnings Report

    Baxter Exhibits Strong 1Q16 Performance, Beat Estimates

    On April 26, 2016, Baxter International (BAX) released its 1Q16 earnings. After the announcement, Baxter’s share price rose ~1% from $43.63 on April 25, 2016, due to the company’s better-than-expected 1Q16 results.

    By Sarah Collins
  • uploads///ST UDE
    Fund Managers

    Millennium Management adds new position in St. Jude Medical

    St. Jude Medical, Inc. is a global medical device company founded in 1976. It has more than 20 principal operations and manufacturing facilities worldwide.

    By Adam Rogers
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    A Brief Recap of the Abbott–Alere Deal Developments

    Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Reveal LINQ May See Robust Demand Trends Going Forward

    In February 2014, Medtronic (MDT) launched the smallest insertable cardiac monitor, Reveal LINQ, after securing 510K clearance from the FDA and the CE Mark from the European Commission.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Aims to Recapture Share in Pacemaker Market in 2018

    In 1Q18, Medtronic (MDT) reported a low-single-digit drop in global revenues earned from pacemakers sold to bradycardia patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Atrial Fibrillation Ablation Could Be a Short-Term Growth Driver for MDT

    More than 33 million patients suffer from AF, the most common form of heart arrhythmia. About 30% of these patients respond to antiarrhythmic drugs (or AAD).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Expands Capabilities of Implantable Cardioverter Defibrillators

    On May 2, 2016, the FDA approved Medtronic’s (MDT) Visia AF and Visia AF MRI Surescan. These devices are single-chamber implantable cardioverter defibrillators (or ICDs) capable of detecting asymptomatic and undiagnosed atrial fibrillation.

    By Margaret Patrick
  • uploads///ablation
    Company & Industry Overviews

    How FDA Approval of EnSite Precision Will Benefit St. Jude’s

    The EnSite Precision cardiac mapping system enables accurate diagnosis and treatment of cardiac arrhythmias.

    By Sarah Collins
  • uploads///abbott st jude
    Company & Industry Overviews

    FTC Approved Abbott’s Acquisition of St. Jude Medical

    The FTC (Federal Trade Commission) has approved the $25 billion acquisition of St. Jude Medical (STJ) by Abbott Laboratories (ABT) subject to certain conditions.

    By Sarah Collins
  • uploads///product pipeline
    Company & Industry Overviews

    Inside Edwards Lifesciences’ THV Product Pipeline and Future Growth Estimates

    Edwards Lifesciences (EW) has a robust product pipeline in its THV (transcatheter heart valve) segment, with Sapien 3 as the segment’s leading product.

    By Sarah Collins
  • uploads///segments
    Company & Industry Overviews

    Trial Data Affirms Positive Results of HeartLogic Diagnostic Service

    Developed by Boston Scientific (BSX), HeartLogic is a system of sensors that can be attached to defibrillator devices. These sensors can monitor the patient and predict heart failure events.

    By Sarah Collins
  • uploads///cvg
    Earnings Report

    Understanding Medtronic’s Weak CVG Segment Performance in Fiscal 2Q17

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.6 billion came from Medtronic’s CVG segment, representing ~35% of the company total.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Edwards Lifesciences Updates 2016 Guidance after 3Q16 Earnings

    Edwards Lifesciences revised its 2016 guidance after reporting a strong 3Q16. The company maintained its sales guidance for the year at the high end of the $2.7 billion–$3 billion range.

    By Sarah Collins
  • uploads///PROFITABILITY
    Earnings Report

    How EW’s Gross Profit Margins Were Affected in 3Q16

    Edwards Lifesciences (EW) reported falling revenue in 3Q16. Its gross profit margin fell and was reported to be ~72.8% of its total revenue, compared to ~76.2% in 2Q16.

    By Sarah Collins
  • uploads///valiant captivia
    Company & Industry Overviews

    New Data Affirm Benefits of Medtronic’s Valiant Captivia

    On September 20, 2016, Medtronic posted its new safety and efficacy data for its Valiant Captivia Thoracic Stent Graft System.

    By Sarah Collins
  • uploads///medical optics
    Company & Industry Overviews

    The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics

    On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.

    By Sarah Collins
  • uploads///segment performance
    Earnings Report

    Analyzing Medtronic’s Sales Growth by Segment in 1Q17

    Medtronic (MDT) operates under four segments: Cardiac and Vascular Group (or CVG), Minimally Invasive Therapies Group (or MITG), Restorative Therapies Group (or RTG), and Diabetes Group.

    By Sarah Collins
  • uploads///capital allocation
    Company & Industry Overviews

    What’s BSX’s Capital Allocation Strategy Going Forward?

    In August 2015, BSX acquired American Medical Systems’ male urology business for $1.6 billion in cash and milestone-based payments of $50 million.

    By Sarah Collins
  • uploads///business strategy
    Company & Industry Overviews

    The Business Strategies Driving Boston Scientific’s Growth

    Boston Scientific registered emerging market sales growth of approximately 13% in 2015, representing a steady growth in international markets.

    By Sarah Collins
  • uploads///medsurg
    Company & Industry Overviews

    Understanding Boston Scientific’s MedSurg Segment

    Boston Scientific’s (BSX) MedSurg segment contributes around 33% to the company’s total revenues and is the company’s second-largest segment.

    By Sarah Collins
  • uploads///segment
    Company & Industry Overviews

    A Brief Look at Boston Scientific’s Business Model

    Boston Scientific’s (BSX) Cardiovascular segment consists of minimally invasive technologies to treat patients with a wide range of heart and vascular diseases. It is BSX’s largest business segment and generated ~39% of the company’s total revenues in 2015.

    By Sarah Collins
  • uploads///profitability
    Earnings Report

    Baxter’s 1Q16 Profitability and 2016 Guidance

    Baxter International (BAX) revised its 2016 guidance as the company reported a strong 1Q16. Sales guidance for the year is updated from the 2%–3% range to approximately 3%.

    By Sarah Collins
  • uploads///STJ ABT portfolio
    Miscellaneous

    Rationale for the St. Jude Medical-Abbott Merger Transaction

    Abbott Labs is buying St. Jude Medical for about $30 billion in cash, stock, and assumed debt to become a dominant player in the cardiovascular health space.

    By Brent Nyitray, CFA, MBA
  • uploads///STJ ABT spread
    Miscellaneous

    Abbott Buys St. Jude Medical for $85 per Share in Cash and Stock

    On April 28, Abbott Labs and St. Jude Medical announced an agreement where Abbott will buy St. Jude for $30 billion in cash, stock, and assumed debt.

    By Brent Nyitray, CFA, MBA
  • uploads///thoratec integration
    Company & Industry Overviews

    Thoratec Acquisition: The Impact on St. Jude’s Growth Potential

    On October 8, 2015, St. Jude Medical (STJ) completed the acquisition of Thoratec for $3.3 billion in net cash consideration. It’s St. Jude’s largest acquisition ever.

    By Sarah Collins
  • uploads///hf
    Company & Industry Overviews

    St. Jude’s Heart Failure Segment: Performance and Opportunities

    St. Jude Medical’s (STJ) heart failure therapy area generated sales of $4 billion and witnessed mid-single-digit growth in 2015.

    By Sarah Collins
  • uploads///revenue segmentation
    Company & Industry Overviews

    St. Jude Medical’s Market Position and Opportunities

    St. Jude Medical has a comprehensive product portfolio in the atrial fibrillation and heart failure therapy areas. The acquisition of Thoratec added to its heart failure therapy product segment.

    By Sarah Collins
  • uploads///TRIAL RESULTS
    Company & Industry Overviews

    A Look at Edwards Lifesciences’ Future Opportunities

    Currently, Edwards Lifesciences’ Sapien 3 and Sapien XT are approved by the FDA to be used in high-risk patients only.

    By Sarah Collins
  • uploads///RD Pipeline
    Company & Industry Overviews

    Probing Medtronic’s Research and Development Pipeline

    Medtronic spent ~$1.6 billion—approximately 8.1% of its total sales—on research and development programs in fiscal 2015.

    By Sarah Collins
  • uploads///segment revenue breakdown
    Company & Industry Overviews

    A Key Breakdown of Medtronic’s Business Model

    Medtronic generates revenue through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies, and the Diabetes Group.

    By Sarah Collins
  • uploads///cardiovascular device segments
    Company & Industry Overviews

    How Are Cardiovascular Devices Classified?

    The US cardiovascular device market is dominated by cardiac rhythm management (or CRM) devices.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    IHI Rose Marginally to Outperform SPY on October 12

    On October 12, the iShares US Medical Devices ETF rose by 0.15% to close at $115.35. The broader market SPDR S&P 500 ETF (SPY) rose by 0.09%.

    By Peter Neil
  • uploads///Total IG Bond Issuance for WE September
    Fund Managers

    Disney Issues $2.0 Billion in High-Grade Bonds Last Week

    US corporates were the biggest issuers of high-grade bonds last week, making up 54.2% of all issues. The Walt Disney Company (DIS) issued A2/A rated high-grade bonds worth $2.0 billion.

    By Lynn Noah
  • uploads///northeast
    Fund Managers

    Millennium Management decreases position in Northeast Utilities

    Northeast Utilities reported a 12% rise in profits on lower operating costs and increased investments in big power transmission projects around New England.

    By Adam Rogers
  • uploads///blood pressure
    Healthcare

    Is renal denervation a new medical device stocks cash cow?

    No US companies have approved renal denervation devices in the US market, but they’re in the process of testing and selling these devices.

    By Amritpal Khalsa
  • uploads///pricing e
    Healthcare

    Medtronic purchases Cardiocom: Bad for medical device industry?

    Medtronic has always been considered a bellwether for the medical device industry because of its pure focus on the device market. Yet that changed in mid-August, as Medtronic announced its acquisition of Cardiocom.

    By Amritpal Khalsa
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.